Bellicum to Participate in Two Upcoming Virtual Investor Conferences
Bellicum Pharmaceuticals (NASDAQ:BLCM) announced participation in two virtual investor conferences. The first is the Wells Fargo 2020 Virtual Healthcare Conference on September 9, 2020, at 12:40 p.m. EDT, featuring an analyst moderated discussion. The second is the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 2:30 p.m. EDT, which will include a presentation. Live webcasts and archived versions of the events will be accessible on the company’s website.
- None.
- None.
HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual investor conferences.
Conference Details:
Wells Fargo 2020 Virtual Healthcare Conference
Date/Time: Wednesday, September 9, 2020 at 12:40 p.m. EDT
Format: Analyst Moderated Discussion
H.C. Wainwright 22nd Annual Global Investment Conference
Date/Time: Tuesday, September 15, 2020 at 2:30 p.m. EDT
Format: Presentation
A live webcast of the analyst moderated discussion session at Wells Fargo and the H.C. Wainwright presentation may be accessed from the Events & Presentation section of the Bellicum website. An archived version of each webcast will be available for replay immediately following the event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and CAR-NK cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com.
Source: Bellicum Pharmaceuticals
Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
858-356-5932
Robert.uhl@westwicke.com
FAQ
What is the date and time of Bellicum Pharmaceuticals' participation in the Wells Fargo 2020 Virtual Healthcare Conference?
When will Bellicum Pharmaceuticals present at the H.C. Wainwright 22nd Annual Global Investment Conference?
How can I access the webcasts for Bellicum Pharmaceuticals' investor conferences?
What technologies are Bellicum Pharmaceuticals developing for cancer therapy?
What are the names of Bellicum Pharmaceuticals' product candidates?
